SEC Form 3 filed by new insider Asher-Topilsky Lilach
$KMDA
Biotechnology: Pharmaceutical Preparations
Health Care
| FORM 3 | UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940 |
| |||||||||||||||
1. Name and Address of Reporting Person*
(Street)
(Country) | 2. Date of Event Requiring Statement
(Month/Day/Year) 03/18/2026 | 3. Issuer Name and Ticker or Trading Symbol
KAMADA LTD [ KMDA ] | |||||||||||||||
| 3a. Foreign Trading Symbol
| 5. If Amendment, Date of Original Filed
(Month/Day/Year) | ||||||||||||||||
| 4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
| 6. Individual or Joint/Group Filing (Check Applicable Line)
| ||||||||||||||||
| Table I - Non-Derivative Securities Beneficially Owned | |||
|---|---|---|---|
| 1. Title of Security (Instr. 4) | 2. Amount of Securities Beneficially Owned (Instr. 4) | 3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) | 4. Nature of Indirect Beneficial Ownership (Instr. 5) |
| Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities) | |||||||
|---|---|---|---|---|---|---|---|
| 1. Title of Derivative Security (Instr. 4) | 2. Date Exercisable and Expiration Date (Month/Day/Year) | 3. Title and Amount of Securities Underlying Derivative Security (Instr. 4) | 4. Conversion or Exercise Price of Derivative Security | 5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) | 6. Nature of Indirect Beneficial Ownership (Instr. 5) | ||
| Date Exercisable | Expiration Date | Title | Amount or Number of Shares | ||||
| Employee Stock Option (right to buy) | 03/25/2021(1) | 09/25/2026 | Ordinary Shares | 6,625 | $7.6(2)(3) | I | Held by trustee(4) |
| Employee Stock Option (right to buy) | 03/25/2022(1) | 09/25/2026 | Ordinary Shares | 6,625 | $7.6(2)(3) | I | Held by trustee(4) |
| Employee Stock Option (right to buy) | 03/25/2023(1) | 09/25/2026 | Ordinary Shares | 6,625 | $7.6(2)(3) | I | Held by trustee(4) |
| Employee Stock Option (right to buy) | 12/22/2023(1) | 06/22/2029 | Ordinary Shares | 7,500 | $6.17(2)(3) | I | Held by trustee(4) |
| Employee Stock Option (right to buy) | 03/25/2024(1) | 09/25/2026 | Ordinary Shares | 6,625 | $7.6(2)(3) | I | Held by trustee(4) |
| Employee Stock Option (right to buy) | 12/22/2024(1) | 06/22/2029 | Ordinary Shares | 7,500 | $6.17(2)(3) | I | Held by trustee(4) |
| Employee Stock Option (right to buy) | 12/22/2025(1) | 06/22/2029 | Ordinary Shares | 7,500 | $6.17(2)(3) | I | Held by trustee(4) |
| Employee Stock Option (right to buy) | 12/22/2026(1) | 06/22/2029 | Ordinary Shares | 7,500 | $6.17(2)(3) | I | Held by trustee(4) |
| Explanation of Responses: |
| 1. Options vest in four equal installments, with 25% vesting on each of the four anniversaries of the date of grant. |
| 2. All exercise prices presented in U.S. dollars represent a convenience conversion from NIS based on the exchange rate published by the Bank of Israel as of April 16, 2026. |
| 3. The exercise price of the options was adjusted from $7.85 to $7.60 and from $6.42 to $6.17, respectively, pursuant to the provisions of the Company's 2011 Share Award Plan in connection with a cash dividend distribution declared by the Company's board of directors on March 11, 2026. There are no other changes to the terms and conditions of the option award. |
| 4. Held by trustee under the Company's 2011 Share Award Plan. |
| /S/ Lilach Asher Topilsky | 04/16/2026 | |
| ** Signature of Reporting Person | Date | |
| Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly. | ||
| * If the form is filed by more than one reporting person, see Instruction 5 (b)(v). | ||
| ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a). | ||
| Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure. | ||
| Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number. | ||
| * Form 3: SEC 1473 (03-26) | ||